Exactech (EXAC) Extends Knee Development License with Hospital for Special Surgery
More News related to EXAC
- Baird Upgrades Exactech (EXAC) to Outperform
- Exactech (EXAC) Tops Q3 EPS by 1c; Issues Mixed Guidance for Q4 and FY
- Exactech (EXAC) reports Q3 EPS of $0.21; Guides
- Exactech Q3 Revenue $42.4M; Net Income $2.7M or $0.21 EPS
- Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
More News related to Corporate News
- Hyperdynamics (HDY) Will Sell 7.22M Shares at $0.90, Raising $6.5M Thru Offering
- HQ Sustainable Maritime (HQS) Files $50M Mixed Shelf
- Human Genome Sciences (HGSI) Prices 15M Common Offering at $26.75/Share; Offering Increased from 12.5M Common
- Vertex Pharma (VRTX) Prices 11.5M Shares at $38.50/Share
- Bank of America (BAC) $18.8B Convertible Preferred Offering Coming Monday
Exactech, Inc. (Nasdaq: EXAC) announced that it has extended its relationship with Hospital for Special Surgery, New York, NY, to further advance implant designs for total knee replacement surgery. Exactech plans to introduce a new knee implant as an evolution of its flagship Optetrak(R) brand, as a result of this continued collaboration. Limited release of the new knee is expected in the second half of 2009.
Exactech and Hospital for Special Surgery began collaborating on knee implant development in 1992, which culminated in Exactech's licensure of Hospital for Special Surgery technologies. The resulting Optetrak comprehensive knee system has been marketed by Exactech since 1995 and represents approximately 45 percent of the company's sales. For a multitude of patients in more than 30 countries around the world, Optetrak has demonstrated excellent long-term clinical results.
Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians.
Related Categories
Corporate NewsStocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
